Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $11.67 Consensus Price Target from Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has been assigned a consensus rating of "Buy" from the eight brokerages that are presently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $11.67.

ACRS has been the topic of a number of analyst reports. HC Wainwright raised shares of Aclaris Therapeutics from a "neutral" rating to a "buy" rating and set a $20.00 price objective on the stock in a research report on Monday, December 23rd. Scotiabank began coverage on Aclaris Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $15.00 price target on the stock. StockNews.com cut Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 8th. Finally, Cantor Fitzgerald initiated coverage on Aclaris Therapeutics in a research report on Tuesday, March 18th. They set an "overweight" rating on the stock.

Aclaris Therapeutics Price Performance

NASDAQ ACRS traded up $0.07 during trading on Friday, reaching $1.55. 311,406 shares of the company's stock traded hands, compared to its average volume of 890,589. Aclaris Therapeutics has a 12-month low of $0.95 and a 12-month high of $5.17. The firm has a market cap of $166.73 million, a price-to-earnings ratio of -2.97 and a beta of 0.53. The company's 50 day simple moving average is $2.03 and its two-hundred day simple moving average is $2.24.

Hedge Funds Weigh In On Aclaris Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ACRS. Jefferies Financial Group Inc. lifted its stake in Aclaris Therapeutics by 253.9% during the 4th quarter. Jefferies Financial Group Inc. now owns 40,700 shares of the biotechnology company's stock valued at $101,000 after acquiring an additional 29,200 shares during the period. Alpine Global Management LLC acquired a new position in Aclaris Therapeutics during the fourth quarter valued at $38,000. Velan Capital Investment Management LP purchased a new stake in Aclaris Therapeutics in the fourth quarter valued at $67,000. Squarepoint Ops LLC grew its position in Aclaris Therapeutics by 108.3% during the 4th quarter. Squarepoint Ops LLC now owns 292,892 shares of the biotechnology company's stock worth $726,000 after purchasing an additional 152,312 shares during the period. Finally, Man Group plc purchased a new position in shares of Aclaris Therapeutics during the 4th quarter valued at about $133,000. Institutional investors and hedge funds own 98.34% of the company's stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.